Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma

Published:2019-10-09 Issue: Volume:9 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Billon Emilien,Walz Jochen,Brunelle Serge,Thomassin Jeanne,Salem Naji,Guerin Mathilde,Vicier Cecile,Dermeche Slimane,Albiges Laurence,Tantot Florence,Nenan Soazig,Pignot Geraldine,Gravis Gwenaëlle

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference32 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer.,2015

2. Current and future systemic treatments for renal cell carcinoma;Fisher;Semin Cancer Biol.,2013

3. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol.,2009

4. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N Engl J Med.,2015

5. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial;Motzer;Lancet Oncol.,2013

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis;Case Reports in Oncology;2024-01-05

2. Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma;Cancers;2023-03-31

3. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data;Frontiers in Oncology;2023-01-13

4. Mechanisms of dermatological toxicities to immune checkpoint inhibitor cancer therapies;Clinical and Experimental Dermatology;2022-11-01

5. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report;Frontiers in Immunology;2022-09-16